StockDriftsStockDriftsTop 3 Memorial Sloan Kettering Cancer Center Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| GDX | VANECK ETF TRUST | 80.92% | 738.5K | $19.9M | +0.00%(+0) | — | 2023-09-30 | |
| ORIC | ORIC PHARMACEUTICALS INC | 14.84% | 602.3K | $3.6M | +0.00%(+0) | — | 2023-09-30 | |
| YMAB | Y-MABS THERAPEUTICS INC | 4.24% | 191.2K | $1.0M | +0.00%(+0) | — | 2023-09-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — |
| Top 20 Holdings Unweighted | — | — | — | — |
Memorial Sloan Kettering Cancer Center reports $24.56M in US-listed equity holdings across 3 positions in its most recent 13F filing. Its largest disclosed positions are GDX (80.9%), ORIC (14.8%) and YMAB (4.2%). Figures reflect the Q3 2023 filing.
Sign up free to track Memorial Sloan Kettering Cancer Center, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Memorial Sloan Kettering Cancer Center’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1566787). View Memorial Sloan Kettering Cancer Center’s 13F filings on SEC